JAK Inhibitor Selection in Myelofibrosis: A Clinical Decision-Making Approach

home / expert-perspective-tumor-board / jak-inhibitor-selection-in-myelofibrosis-a-clinical-decision-making-approach

Aaron Gerds, MD; Jeanne Palmer, MD; Prithviraj Bose, MD; and Jonathan Abbas, MD, examine the comprehensive management of myelofibrosis, from molecular mechanisms through various disease stages, focusing on risk stratification, treatment sequencing, quality-of-life outcomes, and the integration of emerging therapies into evidence-based clinical practice.

EP. 1: Myelofibrosis Disease Biology: From Molecular Mechanisms to Clinical Phenotypes and Therapeutic Targets

Aaron T. Gerds, MD, MS;Jeanne Palmer, MD

January 27th 2025

Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations, ultimately informing the development of targeted therapeutic approaches for this bone marrow disorder.

Watch

EP. 2: Patient-Centered Care in Myelofibrosis: Managing Expectations and Quality-of-Life Outcomes

Aaron T. Gerds, MD, MS;Jeanne Palmer, MD

January 27th 2025

Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with myelofibrosis through comprehensive symptom management, shared decision-making, and careful attention to patient goals and expectations.

Watch

EP. 3: Risk-Stratified Approaches in Newly Diagnosed Myelofibrosis: Clinical Decision-Making for Intermediate-2 Disease

Aaron T. Gerds, MD, MS;Jeanne Palmer, MD

February 3rd 2025

Panelists discuss how risk stratification tools and patient-specific factors guide treatment selection and timing of interventions for patients with newly diagnosed intermediate 2–risk myelofibrosis, with a focus on optimizing clinical outcomes.

Watch

EP. 4: COMFORT Studies in Context: Understanding Response Parameters and Long-Term Outcomes

Aaron T. Gerds, MD, MS;Jeanne Palmer, MD

February 3rd 2025

Panelists discuss how the landmark COMFORT trials have shaped the understanding of Janus kinase inhibitor therapy response criteria and long-term clinical outcomes in patients with myelofibrosis, providing crucial data to inform current treatment approaches.

Watch

EP. 5: Clinical Case Evolution: Disease Progression Patterns After Initial Therapy

Aaron T. Gerds, MD, MS;Jeanne Palmer, MD

February 10th 2025

Panelists discuss how myelofibrosis can evolve following initial treatment, examining common patterns of disease progression and strategies for adapting therapeutic approaches based on individual patient response and changing clinical parameters.

Watch